s infusion 500mg "KHK"
General name
Rituximab(genetically modified)[rituximab successor 1]
Efficacy and Effect
CD20-Positive B-cell non-Hodgkin lymphoma
CD20-Positive B-cell lymphatic proliferative disease under immunosuppressive conditions
Granuloma Vegena, microscopic multiple vasculitis
Usage and dosage
CD20 positive B-cell non-Hodgkin's lymphoma.
Typically, adults, rituximab (recombinant)[rituximab trailing 1]as a 1-dose 375mg/m 2 to intravenous infusion at intervals of one week. The maximum number of doses is 8 times. When used in combination with other anti-malignant tumor agents, according to the administration interval of the anti-malignant tumor agent in combination, administered once per cycle.
When used for maintenance therapy, typically, in adults, rituximab (recombinant) [rituximab subsequent 1] The amount of 375mg/M 2 is intravenous infusion. The administration interval is an indication of eight weeks, the maximum number of doses is 12 times.
In the case of CD20 positive B-cell lymphatic proliferative disease under immunosuppressive conditions>
Usually, rituximab (recombinant) [rituximab subsequent 1] The amount 375mg/M 2 as a 1-week interval to intravenous drip. The maximum number of doses is 8 times.
(Vegena) for granuloma and microscopic vasculitis.
Typically, in adults, rituximab (recombinant) [rituximab trailing 1] 1 dose 375mg/m 2 per week interval 4 times intravenous infusion.
Packaging
Rituximab BS intravenous infusion 100mg "KHK": 10ml vial × 1
Rituximab BS drip-500mg "KHK": 50ml vial × 1
Approval date September 27, 2017
Drug price listing on November 29, 2017
|
